Annual Cash & Cash Equivalents
$2.77 M
-$2.20 M-44.30%
01 December 2023
Summary:
TransCode Therapeutics annual cash & cash equivalents is currently $2.77 million, with the most recent change of -$2.20 million (-44.30%) on 01 December 2023. During the last 3 years, it has fallen by -$18.06 million (-86.71%). RNAZ annual cash & cash equivalents is now -86.71% below its all-time high of $20.83 million, reached on 31 December 2021.RNAZ Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$1.88 M
-$1.48 M-44.08%
01 September 2024
Summary:
TransCode Therapeutics quarterly cash and cash equivalents is currently $1.88 million, with the most recent change of -$1.48 million (-44.08%) on 01 September 2024. Over the past year, it has dropped by -$891.70 thousand (-32.22%). RNAZ quarterly cash and cash equivalents is now -91.66% below its all-time high of $22.50 million, reached on 30 September 2021.RNAZ Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RNAZ Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -32.2% |
| 3 y3 years | -86.7% | -91.0% |
| 5 y5 years | +1253.3% | - |
RNAZ Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -86.7% | at low | -91.0% | +15.6% |
| 5 y | 5 years | -86.7% | +1253.3% | -91.7% | +2256.7% |
| alltime | all time | -86.7% | +1253.3% | -91.7% | +2256.7% |
TransCode Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.88 M(-44.1%) |
| June 2024 | - | $3.35 M(-31.7%) |
| Mar 2024 | - | $4.91 M(+77.5%) |
| Dec 2023 | $2.77 M(-44.3%) | $2.77 M(-62.9%) |
| Sept 2023 | - | $7.45 M(+108.6%) |
| June 2023 | - | $3.57 M(+120.2%) |
| Mar 2023 | - | $1.62 M(-67.3%) |
| Dec 2022 | $4.97 M | $4.97 M(-43.5%) |
| Sept 2022 | - | $8.79 M(-34.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2022 | - | $13.44 M(-20.3%) |
| Mar 2022 | - | $16.85 M(-19.1%) |
| Dec 2021 | $20.83 M(+2415.2%) | $20.83 M(-7.4%) |
| Sept 2021 | - | $22.50 M(>+9900.0%) |
| June 2021 | - | $79.60 K(-19.6%) |
| Mar 2021 | - | $99.00 K(-88.0%) |
| Dec 2020 | $828.00 K(+304.9%) | - |
| Dec 2020 | - | $828.00 K |
| Dec 2019 | $204.50 K | - |
FAQ
- What is TransCode Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for TransCode Therapeutics?
- What is TransCode Therapeutics quarterly cash and cash equivalents year-on-year change?
What is TransCode Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of RNAZ is $2.77 M
What is the all time high annual cash & cash equivalents for TransCode Therapeutics?
TransCode Therapeutics all-time high annual cash & cash equivalents is $20.83 M
What is TransCode Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RNAZ is $1.88 M
What is the all time high quarterly cash and cash equivalents for TransCode Therapeutics?
TransCode Therapeutics all-time high quarterly cash and cash equivalents is $22.50 M
What is TransCode Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, RNAZ quarterly cash and cash equivalents has changed by -$891.70 K (-32.22%)